S&P 500   3,357.16 (-0.68%)
DOW   29,129.06 (-0.92%)
QQQ   233.51 (-0.48%)
AAPL   316.32 (-2.66%)
FB   216.25 (+0.97%)
MSFT   186.25 (+0.49%)
GOOGL   1,512.97 (-0.38%)
AMZN   2,133.03 (-0.09%)
CGC   22.21 (+0.36%)
NVDA   289.37 (-0.14%)
BABA   218.18 (-0.66%)
MU   57.25 (-2.14%)
GE   12.77 (-0.47%)
TSLA   841.98 (+5.24%)
AMD   56.73 (+2.57%)
T   38.10 (-0.39%)
ACB   1.60 (+0.63%)
F   8.05 (-0.62%)
PRI   135.23 (-1.18%)
BAC   34.07 (-2.24%)
GILD   67.15 (-0.61%)
S&P 500   3,357.16 (-0.68%)
DOW   29,129.06 (-0.92%)
QQQ   233.51 (-0.48%)
AAPL   316.32 (-2.66%)
FB   216.25 (+0.97%)
MSFT   186.25 (+0.49%)
GOOGL   1,512.97 (-0.38%)
AMZN   2,133.03 (-0.09%)
CGC   22.21 (+0.36%)
NVDA   289.37 (-0.14%)
BABA   218.18 (-0.66%)
MU   57.25 (-2.14%)
GE   12.77 (-0.47%)
TSLA   841.98 (+5.24%)
AMD   56.73 (+2.57%)
T   38.10 (-0.39%)
ACB   1.60 (+0.63%)
F   8.05 (-0.62%)
PRI   135.23 (-1.18%)
BAC   34.07 (-2.24%)
GILD   67.15 (-0.61%)
S&P 500   3,357.16 (-0.68%)
DOW   29,129.06 (-0.92%)
QQQ   233.51 (-0.48%)
AAPL   316.32 (-2.66%)
FB   216.25 (+0.97%)
MSFT   186.25 (+0.49%)
GOOGL   1,512.97 (-0.38%)
AMZN   2,133.03 (-0.09%)
CGC   22.21 (+0.36%)
NVDA   289.37 (-0.14%)
BABA   218.18 (-0.66%)
MU   57.25 (-2.14%)
GE   12.77 (-0.47%)
TSLA   841.98 (+5.24%)
AMD   56.73 (+2.57%)
T   38.10 (-0.39%)
ACB   1.60 (+0.63%)
F   8.05 (-0.62%)
PRI   135.23 (-1.18%)
BAC   34.07 (-2.24%)
GILD   67.15 (-0.61%)
S&P 500   3,357.16 (-0.68%)
DOW   29,129.06 (-0.92%)
QQQ   233.51 (-0.48%)
AAPL   316.32 (-2.66%)
FB   216.25 (+0.97%)
MSFT   186.25 (+0.49%)
GOOGL   1,512.97 (-0.38%)
AMZN   2,133.03 (-0.09%)
CGC   22.21 (+0.36%)
NVDA   289.37 (-0.14%)
BABA   218.18 (-0.66%)
MU   57.25 (-2.14%)
GE   12.77 (-0.47%)
TSLA   841.98 (+5.24%)
AMD   56.73 (+2.57%)
T   38.10 (-0.39%)
ACB   1.60 (+0.63%)
F   8.05 (-0.62%)
PRI   135.23 (-1.18%)
BAC   34.07 (-2.24%)
GILD   67.15 (-0.61%)
Log in

NASDAQ:PCYC - Pharmacyclics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pharmacyclics, Inc is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:PCYC
CUSIP71693310
WebN/A
Phone+1-302-6587581

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive PCYC News and Ratings via Email

Sign-up to receive the latest news and ratings for PCYC and its competitors with MarketBeat's FREE daily newsletter.


Pharmacyclics (NASDAQ:PCYC) Frequently Asked Questions

What is Pharmacyclics' stock symbol?

Pharmacyclics trades on the NASDAQ under the ticker symbol "PCYC."

Has Pharmacyclics been receiving favorable news coverage?

News headlines about PCYC stock have been trending neutral on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Pharmacyclics earned a news impact score of 0.3 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the near term. View News Stories for Pharmacyclics.

Who are some of Pharmacyclics' key competitors?

What other stocks do shareholders of Pharmacyclics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pharmacyclics investors own include Celgene (CELG), Gilead Sciences (GILD), Baidu (BIDU), Regeneron Pharmaceuticals (REGN), Netflix (NFLX), Jazz Pharmaceuticals (JAZZ), Biogen (BIIB), Cara Therapeutics (CARA), Intercept Pharmaceuticals (ICPT) and Ionis Pharmaceuticals (IONS).

How can I contact Pharmacyclics?

Pharmacyclics' mailing address is 1 N Waukegan Rd, NORTH CHICAGO, IL 60064-1802, United States. The biopharmaceutical company can be reached via phone at +1-302-6587581.


MarketBeat Community Rating for Pharmacyclics (NASDAQ PCYC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  469 (Vote Outperform)
Underperform Votes:  401 (Vote Underperform)
Total Votes:  870
MarketBeat's community ratings are surveys of what our community members think about Pharmacyclics and other stocks. Vote "Outperform" if you believe PCYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel